Global Burden of Kidney Disease High, Inequities in Care Common Global Burden of Kidney Disease High, Inequities in Care Common
By 2030, 14.5 million people around the world will have end-stage kidney disease (ESKD), yet only 5.4 million will be treated due to economic, social and political factors. And more than 2 million people will die each year due to little or no access to hemodialysis or kidney transplantation.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 20, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news

Trial Results Unclear for Benefit of Longer Hemodialysis Sessions
THURSDAY, April 18, 2019 -- Intervention uptake was insufficient to allow evaluation of its impact in a pragmatic trial designed to assess the effect of longer hemodialysis duration on death and other outcomes; the findings from the Time to Reduce... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2019 Category: Pharmaceuticals Source Type: news

A case report of massive acetaminophen poisoning treated with a novel "triple therapy": N-acetylcysteine, 4-methylpyrazole, and hemodialysis - Kiernan EA, Fritzges JA, Henry KA, Katz KD.
Massive acetaminophen (N-acetyl-p-aminophenol; APAP) ingestion is characterized by a rapid onset of mitochondrial dysfunction, including metabolic acidosis, lactemia, and altered mental status without hepatotoxicity which may not respond to the standard do... (Source: SafetyLit)
Source: SafetyLit - April 11, 2019 Category: International Medicine & Public Health Tags: Poisoning Source Type: news

Psychoactive Medications in Older Adults on Hemodialysis Psychoactive Medications in Older Adults on Hemodialysis
Are psychoactive medications, such as sedative-hypnotics, and antidepressants with anticholinergic properties, associated with major adverse outcomes among older hemodialysis patients?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2019 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

FTC grants final approval for Fresenius ’ s $2B buyout of NxStage
The U.S. Federal Trade Commission said yesterday that it granted a final order of approval to Fresenius Medical Care (NYSE:FMS; ETR:FRE) for its $2 billion acquisition of NxStage Medical. The approval came with a caveat that the companies divest their assets and rights to research, develop, manufacture, market and sell NxStage’s bloodline tubing sets intended for use during hemodialysis treatment. To mollify the anti-trust regulators, NxStage last July agreed to deal its Medisystems bloodlines business to B. Braun. The final order was approved in a three-to-two vote, according to an FTC posti...
Source: Mass Device - April 10, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Dialysis Featured Mergers & Acquisitions Wall Street Beat Fresenius NxStage Medical Inc. Source Type: news

Pursuit Vascular Announces CE Mark Approval for ClearGuard HD Caps
Milestone opens international markets for the company MAPLE GROVE, Minn., April 3, 2019 -- (Healthcare Sales & Marketing Network) -- Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, today announced that the company... Devices, Regulatory, Product Launch Pursuit Vascular, ClearGuard, Antimicrobial Barrier, hemodialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2019 Category: Pharmaceuticals Source Type: news

Two Therapies for Treating Depression in Dialysis Patients Two Therapies for Treating Depression in Dialysis Patients
Dr Bansal describes a new study that compares CBT and sertraline for depressed patients on hemodialysis for end- stage renal disease.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 1, 2019 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news

Hemodialysis device maker Phraxis raises $6m
Early stage medical device company Phraxis has raised approximately $5.6 million in a new round of equity and options financing, according to a recently posted SEC filing. Phraxis is developing a novel treatment for patients who need vascular access for hemodialysis, according to the company’s website. The St. Paul, Minn.-based company’s first product for commercialization is the InterGraft, a percutaneously delivered arteriovenous shunt intended to provide a unique, non-surgical approach for patients who need vascular access, according to the site. Money in the round came from seven unnamed investors, with the...
Source: Mass Device - March 21, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Phraxis Inc. Source Type: news

Fresenius Awarded Breakthrough Device Designation for Software
Fresenius Medical Care hit a significant milestone last week with its software to enhance its line of hemodialysis machines. FDA granted breakthrough device designation to the  company’s computer-assisted ultrafiltration control software. The software is in development to improve fluid management during hemodialysis and personalize treatments. Fluid management is a critical concern for dialysis patients, as both fluid overload and fluid depletion are associated with adverse cardiovascular events, morbidity and mortality. Working with the CLiC device which enables relative blood volume monitori...
Source: MDDI - March 15, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Fresenius wins FDA breakthrough device nod for fluid management software
Fresenius (NYSE:FMS) said yesterday that it won FDA breakthrough device designation for its computer-assisted ultrafiltration control software intended to improve fluid management during hemodialysis. The Waltham, Mass.-based company said that the software is designed to work with its newer hemodialysis machines using its CLiC device. Fresenius said that with the software, it hopes to create a dialysis machine with embedded intelligent diagnostics to provide computer-assisted recommendations for achieving target levels of relative blood volume. “This new software represents our commitment to driving innovation a...
Source: Mass Device - March 15, 2019 Category: Medical Devices Authors: Fink Densford Tags: Dialysis Featured Food & Drug Administration (FDA) Software / IT Fresenius Source Type: news

St. Paul firm pursuing easier hemodialysis treatments closes on nearly $6 million round
St. Paul-based Phraxis Inc.'s device offers an alternative to a central venous catheter. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 13, 2019 Category: American Health Authors: Alex Wittenberg Source Type: news

St. Paul firm pursuing easier hemodialysis treatments closes on nearly $6 million round
St. Paul-based Phraxis Inc.'s device offers an alternative to a central venous catheter. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 13, 2019 Category: Biotechnology Authors: Alex Wittenberg Source Type: news

Tenapanor Reduces Elevated Serum Phosphate in CKD
FRIDAY, March 8, 2019 -- For hyperphosphatemic patients with chronic kidney disease receiving maintenance hemodialysis, tenapanor significantly reduces elevated serum phosphate, according to a study published online March 7 in the Journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2019 Category: Pharmaceuticals Source Type: news

Cantel Medical slumps on fiscal Q2 misses
Cantel Medical (NYSE:CMD) shares took a hit this week when the medical device company missed the consensus forecast with its fiscal second-quarter results. Little Falls, N.J.-based Cantel posted a -42.1% profit slide to $18.8 million, or 45¢ per share, on sales of $224.5 million for the three months ended Jan. 31, for top-line growth of 5.4% compared with fiscal Q2 2018. Adjusted to exclude one-time items, earnings per share were 57¢, a nickel below the consensus on Wall Street, where analysts were looking for revenues of $226.9 million. “We are pleased to see continued strong double-digit sales growth...
Source: Mass Device - March 1, 2019 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Cantel Medical Corp. Source Type: news

Sertraline, CBT Ease Depression in Patients on Dialysis Sertraline, CBT Ease Depression in Patients on Dialysis
Cognitive-behavioral therapy (CBT) and the selective serotonin reuptake inhibitor sertraline each eased depression among patients undergoing maintenance hemodialysis, a study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news

Fresenius closes $2B NxStage buyout, settles FCPA case for $255m
Fresenius Medical Care (NYSE:FMS; ETR:FRE) said today that it closed the $2 billion acquisition of NxStage Medical and settled self-reported violations of the U.S. Foreign Corrupt Practices Act for nearly $255 million. The $30-per-share deal for the Lawrence, Mass.-based home hemodialysis pioneer, first announced in August 2017, was initially slated to close by the end of that year. But it was delayed several times by the government shutdown this year and by the U.S. Federal Trade Commission, which only cleared the transaction last week. To mollify the anti-trust regulators, NxStage last July agreed to ...
Source: Mass Device - February 26, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Featured Legal News Mergers & Acquisitions Wall Street Beat Fresenius NxStage Medical Inc. Source Type: news

Sertraline Tops CBT for Reducing Depression in Dialysis Patients
TUESDAY, Feb. 26, 2019 -- For patients receiving maintenance hemodialysis, an engagement interview on treatment acceptance has no effect on acceptance of depression treatment, and depression scores are modestly better with sertraline treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 26, 2019 Category: Pharmaceuticals Source Type: news

FTC gives the go ahead to Fresenius, NxStage merger
The U.S. Federal Trade Commission said yesterday that it cleared Fresenius (NYSE:FMS) in its $2 billion acquisition of NxStage Medical (NSDQ:NXTM). As part of the approval, NxStage will have to part ways with its bloodline tubing set business, offloading them to B. Braun, according to the regulatory agency. The vote to approve the merger was split, however, with Republicans Joseph Simons, Noah Phillips and Christine Wilson voting to approve while Democrats Rohit Chopra and Rebeca Slaughter dissented. The FTC said that it had previously filed a complaint suggesting that the merger would harm competition for bloodl...
Source: Mass Device - February 20, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Dialysis Featured Mergers & Acquisitions Fresenius NxStage Medical Inc. Source Type: news

Becton Dickinson wins FDA 510(k) for Wavelinq 4F endoAVF system
Becton Dickinson (NYSE:BDX) said today that it won FDA 510(k) clearance for its WavelinQ 4 French endovascular arteriovenous fistula creation system. The Franklin Lakes, N.J.-based company said that the newly cleared WavelinQ 4F endoAVF system features improved technology that allows for the creation of an AVF in either the ulnar artery and ulnar vein or the radial artery and radial vein. The new ability expands upon the company’s existing indications for its WavelinQ 6F endoAVF system, BD said. “With BD WavelinQ 4F endoAVF system, I can provide my ESRD patients with two additional fistula location op...
Source: Mass Device - February 13, 2019 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Featured Food & Drug Administration (FDA) Regulatory/Compliance Vascular bectondickinson Source Type: news

Effects of Vadadustat on Hemoglobin in Hemodialysis Patients Effects of Vadadustat on Hemoglobin in Hemodialysis Patients
Vadadustat is a potential new treatment for anemia in chronic kidney disease -- but what do we know about its impacts in patients receiving hemodialysis?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2019 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Fresenius launches 2008T BlueStar hemodialysis machine in U.S.
Fresenius Medical Care (NYSE:FMS) said today that it launched its 2008T BlueStar hemodialysis machine, touting more than 30 improvements from previous device models. The Waltham, Mass.-based company said that the new system is intended to allow for simpler operation and maintenance with additional treatment options, and added that the system features a number of newly automated technologies. “The new and enhanced 2008T BlueStar hemodialysis machines provide more than 30 unique enhancements to better serve end stage renal disease patients undergoing dialysis. Our new machines represent a significant step for...
Source: Mass Device - February 11, 2019 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Dialysis Fresenius Source Type: news

Fresenius Medical Care North America Launches 2008T BlueStar(TM) Hemodialysis Machine Across the U.S.
Fresenius Medical Care North America Advances Renal Care with Next Generation Dialysis Delivery System Featuring More Than 30 Enhancements WALTHAM, Mass., Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- Fresenius Medical Care North America's... Devices, Product Launch Fresenius Medical Care, 2008T BlueStar, hemodialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news

Hemodialysis Facility Practices Linked to Patient Outcomes
TUESDAY, Feb. 5, 2019 -- Certain practices in hemodialysis facilities relating to management of fluid volume and intradialytic hypotension are associated with patient outcomes, according to a study published online Feb. 5 in the Clinical Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 5, 2019 Category: Pharmaceuticals Source Type: news

Behind the Invention: Wearable Artificial Kidney
If you've ever known someone who has had to be on dialysis, you know that the quality of life for dialysis patients is not great. First of all, there is a pill burden. "My patients need to eat 20 to 30 pills a day," Victor Gura, MD, an internist, nephrologist, and inventor of the Wearable Artificial Kidney (WAK) told MD&M West attendees on Tuesday. "So one was making a joke. He said 'I could put them in a bowl with some dressing and have a salad'. The bottom line is it's a burden and it's also expensive." In addition to the pill burden, dialysis patients are restricted in the...
Source: MDDI - February 5, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: R & D Design Source Type: news

Peritoneal dialysis cost  saving versus haemodialysis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news

Fruit, Vegetable Intake Very Low in Hemodialysis Population
THURSDAY, Jan. 31, 2019 -- Fruit and vegetable intake is very low in the hemodialysis population, with higher consumption associated with lower mortality, according to a study published online Jan. 31 in the Clinical Journal of the American Society... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2019 Category: Pharmaceuticals Source Type: news

Another Device Gets Added to the Peritoneal Dialysis Mix
AWAK Technologies has been granted a breakthrough device designation from FDA for a wearable and ultra-portable peritoneal dialysis (PD) device. The Singapore-based company’s AWAK PD device allows dialysis to be performed "on-the-go", overcoming the challenge of long hours of therapy and connection to large-size dialysis machines, currently faced by renal patients. The company said FDA’s designation was granted after reviewing the results from the First-In-Human safety trial of AWAK PD device, which was successfully completed in October 2018 at the Singapore General Hospital, S...
Source: MDDI - January 11, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients
A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, approved in the U.S. and elsewhere for HIV-1-infected patients with mild-to-moderate chronic kidney disease, may also work well in those with end-stage renal disease on chronic hemodialysis, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Anxious? Inhaling lavender oil can dramatically reduce your stress, study finds
This study provides promising information on the effect of lavender as one... (Source: NaturalNews.com)
Source: NaturalNews.com - December 21, 2018 Category: Consumer Health News Source Type: news

Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests
Alfacalcidol did not reduce the risk for cardiovascular events in patients without secondary hyperparathyroidism who were undergoing maintenance hemodialysis, the J-DAVID trial found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Nephrology News Source Type: news

Vitamin D Analogue No Help for CV Prevention in Hemodialysis Patients
(MedPage Today) -- Trial limited to patients without secondary hyperparathyroidism (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 13, 2018 Category: Urology & Nephrology Source Type: news

Vitamin D Deficiency and Mortality in Maintenance Dialysis Vitamin D Deficiency and Mortality in Maintenance Dialysis
Findings from a new study highlight the need for clinical trials investigating the effects of vitamin D supplementation among patients receiving hemodialysis.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Fresenius Expands Presence in China With Investments and Acquisitions
Fresenius Medical Care is letting it be known that it wants to have a stronger presence in China, one of the fast-growing emerging markets. Last week the Bad Homberg, Germany-based company announced a ton of acquisitions and investments in dialysis centers and renal hospitals in China. Here’s the breakdown: The company acquired a 70% share of Guangzhou KangNiDaiSi Medical Investment Co., Ltd, which focuses on dialysis and related chronic disease services. KangNiDaiSi has three independent hemodialysis centers under construction in the cities of Guangzhou and Zhaoqing in Guangdong province, which borders H...
Source: MDDI - December 10, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Rockwell Medical, Inc. Appoints New Vice President, Operations
Completes Build-Out of Senior Leadership Team by Stuart Paul WIXOM, Mich., Dec. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company" or "Rockwell Medical") today announced that M... Biopharmaceuticals, Personnel Rockwell Medical, Triferic, ferric pyrophosphate, hemodialysis, Calcitriol (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

Baroreflex function, haemodynamic responses to an orthostatic challenge, and falls in haemodialysis patients - Zanotto T, Mercer TH, van der Linden ML, Traynor JP, Petrie CJ, Doyle A, Chalmers K, Allan N, Price J, Oun H, Shilliday I, Koufaki P.
BACKGROUND: Stage 5 chronic kidney disease patients on haemodialysis (HD) often present with dizziness and pre-syncopal events as a result of the combined effect of HD therapy and cardiovascular disease. The dysregulation of blood pressure (BP) during orth... (Source: SafetyLit)
Source: SafetyLit - December 8, 2018 Category: International Medicine & Public Health Tags: Falls Source Type: news

Foot reflexology found more effective than back massage at improving sleep quality in hemodialysis patients
(Natural News) Patients with kidney problems require hemodialysis, a process that helps purify their blood since their kidneys can’t function normally. However, the treatment may cause side effects, including fatigue and poor sleep quality. To address these health problems, the authors of a study examined the effectiveness of natural remedies like foot reflexology. The researchers... (Source: NaturalNews.com)
Source: NaturalNews.com - December 5, 2018 Category: Consumer Health News Source Type: news

Toxicology Rounds: Clinical Markers Dictate Hemodialysis for Salicylate Toxicity
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - December 1, 2018 Category: Emergency Medicine Tags: Toxicology Rounds Source Type: news

A hemodialysis system, which has modernized through miniaturization; and a patient monitoring system that can monitor more patients and/or more parameters and which are increasingly becoming networked in healthcare facilities increasing the risk for cybersecurity threats.
(Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - November 26, 2018 Category: Medical Devices Authors: ( at SGottliebFDA) Source Type: news

Avenu Medical wins CMS reimbursement for Ellipsys dialysis device
Vascular access system maker Avenu Medical said last Friday it won a HCPCS C-Code from the Centers for Medicare and Medicaid Services for its Ellipsys dialysis device and the endoAVF procedure. The San Juan Capistrano, Calif.-based company’s Ellipsys vascular access system device is designed for use with end-stage renal disease patients who require hemodialysis. The system, which can be used under local or regional anesthesia, uses an ultrasound-guided catheter that delivers a small amount of thermal energy to fuse a permanent anastomosis between the vein and artery to create an AVF. The newly granted HCPCS...
Source: Mass Device - November 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Vascular Avenu Medical Source Type: news

Laugh it off: Even simulated laughter improves your mood
(Natural News) People say that a sense of humor makes life’s troubles easier to bear. However, according to the results of a study, implementing a one-of-a-kind simulated laughter program may also help boost the overall health of an individual who requires hemodialysis. The authors posit that this special program may help improve the quality of life and... (Source: NaturalNews.com)
Source: NaturalNews.com - November 5, 2018 Category: Consumer Health News Source Type: news

Uninsured Patients Experience Delays in Obtaining Arteriovenous Access for Hemodialysis Uninsured Patients Experience Delays in Obtaining Arteriovenous Access for Hemodialysis
Uninsured patients who start in-center hemodialysis with a central venous catheter are less likely than those already on Medicare or Medicaid to obtain arteriovenous fistulas (AVF) or grafts (AVG) by their fourth month of dialysis, when they become Medicare eligible, according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 5, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

ASN: High-Dose, Proactive IV Iron Noninferior in Hemodialysis
THURSDAY, Nov. 1, 2018 -- For patients undergoing maintenance hemodialysis, a high-dose intravenous iron regimen administered proactively is noninferior to a low-dose intravenous iron regimen administered reactively, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Another Hold up for NxStage ’s Merger with Fresenius
Fresenius Medical Care’s $2 billion acquisition of Waltham, MA-based NxStage Medical has been delayed yet again. The Bad Homburg, Germany-based company made plans to pick up NxStage in August of 2017 and the deal was supposed to close sometime this year. However, NxStage said in a regulatory filing that the pending merger could come in February of 2019. The issue around the delay seems to center around Fair Trade Commission concerns. Earlier this year, to help satisfy FTC’s antitrade concerns surrounding the deal, NxStage sold its Blood Lines business to B.Braun for an undisclosed sum. &...
Source: MDDI - November 1, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

ASN: Home Dialysis Associated With Improved Survival
MONDAY, Oct. 29, 2018 -- Home hemodialysis (HHD) is associated with better survival than in-center hemodialysis (IHD) among incident dialysis patients, according to a study presented at the American Society of Nephrology's Kidney Week, held Oct. 23... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 29, 2018 Category: Pharmaceuticals Source Type: news

High-Dose Iron an Option for Maintenance Hemodialysis
(MedPage Today) -- High-dose noninferior to low-dose, required less erythropoiesis-stimulating agent (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 29, 2018 Category: Hematology Source Type: news

Home Hemodialysis Tied to Better Survival in Incident Patients
(MedPage Today) -- Patient's ages (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - October 28, 2018 Category: Urology & Nephrology Source Type: news

Prevalence of depression in Jordanian hemodialysis patients - Awwa IAA, Jallad SG.
Background: Although depression is recognized as the most common psychiatric disorder in hemodialysis patients with a significant negative impact on management and prognosis, we didn ’t find any previous data regarding its prevalence in Jordanian patients... (Source: SafetyLit)
Source: SafetyLit - October 27, 2018 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Fresenius Medical touts Crit-Line hemodialysis fluid management studies
Fresenius Medical Care‘s (NYSE:FMS) renal therapies group today released results from four studies of its Crit-Line monitor that looked to explore the relation between relative blood volume monitoring (RBV-M) and patient outcomes. Data from the studies were presented at the 2018 American Society of Nephrology’s Kidney Week Symposium in San Diego, Calif. Results from two of the studies indicated that managing fluid with RBV-M resulted in reduced hospitalizations for patients new to hemodialysis, and provided a “positive return on investment,” according to a press release. A retrospective database ana...
Source: Mass Device - October 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Fresenius Source Type: news

High-Dose Iron Safe, Effective in Hemodialysis Patients High-Dose Iron Safe, Effective in Hemodialysis Patients
High-dose iron reduces the amount of erythropoiesis-stimulating agent needed to treat dialysis patients with anemia, with no rise in risk for infection or cardiovascular events, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2018 Category: Consumer Health News Tags: Nephrology News Source Type: news

Humacyte launches Phase II vascular trauma Humacyl vessel trial
Humacyte said yesterday it launched a U.S. Phase II trial of its Humacyl investigational human acellular vessel exploring the systems’ use for vascular replacement or reconstruction in patients with life or limb-threatening vascular trauma. The Research Triangle Park, N.C.-based company said it hopes to enroll 40 adult patients at six U.S. sites for the trial, with patient monitoring extending out to 24 months. “As a world leader in trauma research, we are constantly exploring new and innovative approaches to treating life threatening injuries. We look forward to evaluating this bioengineered blood vessel in th...
Source: Mass Device - October 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Vascular Humacyte Source Type: news